Viking Therapeutics announces results from Phase 1 clinical trial of VK2735

Viking Therapeutics announced that new results from the company’s Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735 were featured in an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors in development for the potential treatment of various metabolic disorders such as obesity. Highlights from the oral presentation include newly reported data demonstrating that 28 days of once-weekly treatment with VK2735 resulted in reductions in subjects’ liver fat content and plasma lipid levels, both from baseline and as compared to placebo. Viking is currently conducting the Phase 2 VENTURE trial, a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735, administered subcutaneously, once weekly, for 13 weeks. The VENTURE trial is evaluating the treatment in adults who are obese, or adults who are overweight with at least one weight-related co-morbid condition. The primary endpoint of the study is the percent change in body weight from baseline to Week 13, with secondary and exploratory endpoints evaluating a range of additional safety and efficacy measures.